Nephrology

Natera Reports First Quarter 2024 Financial Results

Retrieved on: 
torsdag, maj 9, 2024
Biotechnology, Genetics, Health, Oncology, Nucleic acid thermodynamics, Nephrology, NTRA, Investment, RHD (gene), Uterine cancer, Research, UBS, Genetic testing, Growth, Disease, DNA, Patient, Kidney transplantation, Chronic kidney disease, Bladder cancer, Breast cancer, Pharmaceutical industry

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the first quarter ended March 31, 2024.

Key Points: 
  • Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the first quarter ended March 31, 2024.
  • Generated total revenues of $367.7 million in the first quarter of 2024, compared to $241.8 million in the first quarter of 2023, an increase of 52.1%.
  • Generated gross margins of 56.7% in the first quarter of 2024, compared to gross margins of 38.7% in the first quarter of 2023.
  • Processed approximately 735,800 tests in the first quarter of 2024, compared to approximately 626,200 tests in the first quarter of 2023, an increase of 17.5%.

Panoramic Health Launches State-of-the-Art Ambulatory Surgery Center in Tampa, Florida

Retrieved on: 
torsdag, maj 9, 2024
Physician, Patient, Nephrology, ASC, Partnership, Dialysis, Tampa General Hospital, Medical director, Infection, FKP, Nursing

TEMPE, Ariz. , May 9, 2024 /PRNewswire/ -- Today, Panoramic Health, kidney care's leading integrated provider group, announced the opening of a new 10,000 square foot, five operating room Ambulatory Surgery Center (ASC) in Tampa, FL in partnership with Florida Kidney Physicians (FKP), Florida's largest nephrology group. This strategic expansion signifies another milestone in Panoramic Health's commitment to keeping providers at the center of care delivery through every step of a patient's treatment, from office visit to bedside.

Key Points: 
  • "The launch of the FKP Tampa Surgery Center marks another successful joint venture developed in partnership with Panoramic-affiliated practices," said Nicholas Carlucci, Chief Growth Officer at Panoramic Health.
  • The newest center, marking the first in Florida for Panoramic Health, adds to the portfolio of outpatient surgery centers owned and operated across the Phoenix and Tucson, Ariz. markets as well as Houston, Texas.
  • "I cannot understate the value of our partnership with Panoramic Health to enable the launch and management of this center, which will be a great asset to the Tampa area."
  • "The new surgery center in Tampa goes beyond traditional surgical creations, offering innovative percutaneous procedures aimed at enhancing patient outcomes," added Dr. Emil Abdulhayoglu, Interventional Nephrologist at Florida Kidney Physicians and Medical Director of FKP Tampa Surgery Center.

FLCCC Alliance Announces Executive Leadership Expansion; Co-Founder Dr. Joseph Varon Appointed to the Board of Directors and Named President and Chief Medical Officer

Retrieved on: 
torsdag, maj 9, 2024
Pulmonology, Nursing care plan, Nephrology, Pneumonia, Central Jersey, Private practice, Research, Patient, Physician, Medicine, Hypertension, Trust, Vaccine, FLCCC, Asthma, Growth, Management

WASHINGTON, May 9, 2024 /PRNewswire/ -- The FLCCC Alliance announced today that Dr. Joseph Varon, one of the original co-founders of the organization, has been named president and chief medical officer; he has also been appointed to the board of directors. A globally recognized front line physician and highly published scientist, Dr. Varon is fluent in seven languages and is also the founder of multiple businesses, possessing outstanding organizational leadership skills that the FLCCC requires to execute the strategic plan formulated last fall to significantly expand its breadth of focus, reach, and global impact.

Key Points: 
  • WASHINGTON, May 9, 2024 /PRNewswire/ -- The FLCCC Alliance announced today that Dr. Joseph Varon, one of the original co-founders of the organization, has been named president and chief medical officer; he has also been appointed to the board of directors.
  • Three other founding FLCCC physicians/scientists have also stepped into expanded leadership roles pursuant to the strategic plan.
  • Dr. Pierre Kory is finalizing the transition of his responsibilities to Dr. Varon over the next 45 days.
  • We could not be where we are today without him," said Dr. Paul Marik, co-founder and chief scientific officer.

US Neurologists Report Route of Administration as a Critical Factor when Evaluating Future Parkinson’s Disease Treatments

Retrieved on: 
torsdag, maj 9, 2024
Nephrology, Gastroenterology, Ophthalmology, Rheumatology, Eli Lilly, DMT, Sun Pharma, AAV, Neurology, Growth, B cell, Disease, Novartis, UCB, Novo Nordisk, Incidence, Patient, GBA1, DMTS, Standard of care, Clinical trial, PD, Dermatology, Pharmaceutical industry

Yet, neurologists are hopeful about new ways to deliver levodopa/carbidopa (the current standard of care), new symptomatic treatments, and potential pathways for future disease modifying treatments (DMTs).

Key Points: 
  • Yet, neurologists are hopeful about new ways to deliver levodopa/carbidopa (the current standard of care), new symptomatic treatments, and potential pathways for future disease modifying treatments (DMTs).
  • Beyond these two anticipated products, one-half of neurologists believe in the possibility of an effective DMT within the next five years.
  • To understand how neurologists would evaluate potential future treatments, Spherix conducted an advanced analysis considering neurologists’ preferences for different modalities, efficacy levels, routes of administration (such as IV infusion, oral, etc.
  • Surprisingly, the results show that the route of administration carries nearly as much weight as efficacy when neurologists evaluate likely utility of future therapies.

Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension

Retrieved on: 
torsdag, maj 9, 2024
HIV/AIDS, Nephrology, FDA, Parkinson's disease, New chemical entity, CTD, Woman, Pulmonary hypertension, Blood, Food, Imatinib, NME, Connective tissue disease, PAH, Partnership, IND, Cardiology, Disease, Therapy, Patent, Ventricular septal defect, HIV, Clinical trial, HERG, Division, Investigational New Drug, Pharmaceutical industry

BOSTON and ATLANTA, May 09, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that the Company has received final meeting minutes from its recent pre-IND meeting with the Division of Cardiology and Nephrology of the U.S. Food and Drug Administration (FDA) for IkT-001Pro (“Pro”) as a candidate treatment for Pulmonary Arterial Hypertension (PAH). Following review of the final meeting minutes, Inhibikase is preparing the Investigational New Drug (IND) application.

Key Points: 
  • Following review of the final meeting minutes, Inhibikase is preparing the Investigational New Drug (IND) application.
  • If approved, IkT-001Pro could be a branded product with all the value drivers of a novel treatment for an indication of high unmet medical need.
  • In parallel, the Company has initiated discussions with potential strategic partners in order to advance the development of Pro for Pulmonary Arterial Hypertension.
  • Pulmonary Arterial Hypertension is a rare disease of the pulmonary microvasculature.

Carna Health Names Leadership Team and Presents Strong Results from Bermuda CKD Screening Program

Retrieved on: 
torsdag, maj 9, 2024
Software, Telemedicine, Virtual Medicine, General Health, Health, Artificial Intelligence, Health Technology, Technology, Other Health, Mortality, Public, Kidney disease, Nephrology, Hospital, Prevalence, Death, Partnership, MSBA, Oscar Health, Joslin Diabetes Center, Intelligence, CKD, Patient, Bill, MPH, Dialysis, Faculty, Ministry, Harvard Medical School, MBA, BBA, Quality of life, Chronic kidney disease, MHA, IBM, Management

Carna Health , a digital health company transforming kidney care, today named its leadership team and released results from a chronic kidney disease (CKD) screening program in Bermuda as the first international recipient of a grant from the Bermuda Health Council Innovation Program.

Key Points: 
  • Carna Health , a digital health company transforming kidney care, today named its leadership team and released results from a chronic kidney disease (CKD) screening program in Bermuda as the first international recipient of a grant from the Bermuda Health Council Innovation Program.
  • “Our shared commitment with Carna Health to develop new screening and monitoring programs for CKD at sites outside the hospital is essential to our partnership.
  • “The results from the screening program in Bermuda demonstrate the feasibility of cost-effective, large-scale population screening and monitoring for CKD – and the high rate of undiagnosed CKD that needs to be addressed so we can prioritize prevention and earlier disease management,” said Carna Health CMO and COO Shika Pappoe, MD, MPH, MBA.
  • In just three days the program surpassed its screening target, drawing more than 550 participants.

American Clinical Research Services Announces Strategic Acquisition of Elixia

Retrieved on: 
onsdag, maj 8, 2024
Health, Infectious Diseases, Neurology, Clinical Trials, Research, Science, Acquisition, Infection, ACRS, ChromeOS, Nephrology, LCM, Medicine, Patient, Specialization, Pharmaceutical industry

American Clinical Research Services (ACRS), a leader in complex clinical research formed by Latticework Capital Management (LCM) in 2022, is pleased to announce the successful acquisition of Elixia, a distinguished multi-specialty clinical research network with operations spanning Florida, Massachusetts, Michigan, and Missouri.

Key Points: 
  • American Clinical Research Services (ACRS), a leader in complex clinical research formed by Latticework Capital Management (LCM) in 2022, is pleased to announce the successful acquisition of Elixia, a distinguished multi-specialty clinical research network with operations spanning Florida, Massachusetts, Michigan, and Missouri.
  • Founded in 2019 by Neal Patel and Jim Crissy, Elixia has rapidly ascended to become a leading clinical trial site network in trials involving specialty patient populations, particularly in nephrology.
  • Neal Patel, co-founder of Elixia, commented on the acquisition, emphasizing the synergistic potential of the combined entities.
  • Coupled with unique patient recruitment capabilities, ACRS provides sponsors and CROs comprehensive patient recruitment and trial execution services.

Otsuka America, Inc’s. Data and Technology Company will Support Rejoyn™ Commercialization & Personalized Patient Engagement

Retrieved on: 
måndag, maj 6, 2024
Mental Health, Health, FDA, Technology, Other Technology, Mobile, Wireless, General Health, APA, Ōtsuka, Nephrology, American Psychiatric Association, Food, OAI, Artificial intelligence, Therapy, DSM-IV codes, Mental health, Patient, OPH, Annual general meeting, Food and Drug Administration, MDD, Pharmaceutical industry

OPH will focus on the patient experience as a core piece of improving how better outcomes might be achieved across nephrology, mental health, and beyond.

Key Points: 
  • OPH will focus on the patient experience as a core piece of improving how better outcomes might be achieved across nephrology, mental health, and beyond.
  • OPH will serve to commercialize Rejoyn™.
  • Otsuka is deepening its commitment to the meaningful role technology can play in the lives of patients and the care teams that surround them.
  • “At this time there is a great desire for alternative therapies and treatments in the mental health space, especially given the outpaced demand in recent years,” said Shah.

Adtalem Global Education Fiscal Third Quarter 2024 Results; Guidance Raised

Retrieved on: 
torsdag, maj 2, 2024
Nursing, Education, Mental Health, Health, Other Health, University, Veterinary, Nurse education, Chamberlain University, Walden University, Nephrology, Perioperative, Social, Emergency nursing, American Nurses Foundation, ACAMS, Emergency Nurses Association, Partnership, Growth, History, Behavior, Black, Physician, Medicine, College, Financial services, Perioperative nursing, ENA, Veterinary medicine, Student, American University, Chamberlain, ATGE

Adtalem Global Education Inc. (NYSE: ATGE), the leading healthcare educator in the United States, today reported third quarter fiscal 2024 results (quarter ended March 31, 2024) reflecting robust operating performance through accelerated total enrollment growth and enhanced profitability.

Key Points: 
  • Adtalem Global Education Inc. (NYSE: ATGE), the leading healthcare educator in the United States, today reported third quarter fiscal 2024 results (quarter ended March 31, 2024) reflecting robust operating performance through accelerated total enrollment growth and enhanced profitability.
  • “Our Growth with Purpose strategy, with its emphasis on operational excellence, continues to accelerate top- and bottom-line performance, permitting us to expand access to high-quality, in-demand programs,” said Steve Beard, president and chief executive officer, Adtalem Global Education.
  • Operating income was $61.7 million, compared with $59.4 million in the prior year; adjusted operating income was $89.8 million, compared with $73.0 million in the prior year.
  • Chamberlain University continues to expand its specialized nursing education that addresses areas of acute nursing shortages through its Practice Ready.

New Executives Join Evergreen Nephrology Leadership Team

Retrieved on: 
torsdag, maj 2, 2024
Kidney disease, Nephrology, Partnership, Patient, Medicine, Assistant, CIO, Evergreen, Chronic kidney disease, Nursing

NASHVILLE, Tenn., May 2, 2024 /PRNewswire/ -- Today, Evergreen Nephrology ("Evergreen"), the leader in value-based kidney care, announced the appointment of two new executives to its leadership team Heather Trafton as President, and Ron Margalit as Chief Information Officer (CIO).

Key Points: 
  • NASHVILLE, Tenn., May 2, 2024 /PRNewswire/ -- Today, Evergreen Nephrology ("Evergreen"), the leader in value-based kidney care, announced the appointment of two new executives to its leadership team Heather Trafton as President, and Ron Margalit as Chief Information Officer (CIO).
  • In her role as President, she will lead Evergreen operations, working with both the central and field operations team to ensure nephrologists have the support they need to provide the best care possible to their patients.
  • "Strong leaders are critical to driving Evergreen's efforts forward, which is why we are excited that Heather Trafton and Ron Margalit have joined the Evergreen team," said Adam Boehler, Executive Chairman of Evergreen Nephrology.
  • Ron's experience developing technology for value-based organizations is a critical asset for Evergreen and our nephrology partners as they improve care for kidney care patients."